CD70-Specific CARs Overcome Cancer Drug Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer, particularly those involving aberrant expression of CD70, are limited by drug resistance and the need for alternative therapeutic approaches.
Innovation Solution
Development of chimeric antigen receptors (CARs) specifically binding to CD70, which are expressed in immune cells such as T cells, enabling targeted recognition and elimination of CD70-expressing cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cancer treatments are used, then existing therapeutic options are available, but drug resistance limits effectiveness
Solution Approach 1:
The patent changes the therapeutic parameter from conventional chemotherapy or immunotherapy to CAR-T cell therapy with CD70-specific scFv, fundamentally altering the mechanism of action to overcome drug resistance. The engineered CAR structure with specific extracellular domains (including CD70-binding scFv) enables T cells to recognize and eliminate CD70-expressing tumor cells through a novel pathway not subject to conventional drug resistance mechanisms.
2Measurement precision
If CD70-specific CARs are developed, then targeted recognition of cancer cells is improved, but the complexity of the therapeutic approach increases
Solution Approach 1:
The CAR is segmented into distinct functional domains: an extracellular domain containing CD70-specific scFv for antigen recognition, a transmembrane domain for cell membrane anchoring, and intracellular signaling domains for T cell activation. This segmentation allows each domain to be optimized independently while maintaining overall functionality, balancing specificity with manageable complexity.
Solution Approach 2:
The CAR construct integrates multiple functions into a single engineered receptor: antigen binding (CD70 recognition), signal transduction, and T cell activation. This multi-functionality reduces the need for separate therapeutic agents while achieving precise target recognition and effective tumor cell elimination.
3Reliability
If adoptive transfer of T cells is used, then cancer treatment promise is achieved, but potential target-driven T cell exhaustion occurs during production
Solution Approach 1:
The CAR design implements local quality by directing the CD70-specific scFv to be expressed exclusively on the surface of adoptively transferred T cells, rather than systemically. This localized expression ensures that only the engineered T cells recognize and respond to CD70-expressing tumor cells, minimizing off-target effects and reducing the risk of T cell exhaustion during production and treatment.
Data Source
AI summary
The disclosure provides CARs (CARs) that specifically bind to CD70. The disclosure further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The disclosure further relates to therapeutic methods for use of these CARs and engineered immune cells comprising these CARs for the treatment of a condition associated with malignant cells expressing CD70 (e.g., cancer).